[go: up one dir, main page]

WO2001049336A1 - Biocompatible hydrogel and method of its production - Google Patents

Biocompatible hydrogel and method of its production Download PDF

Info

Publication number
WO2001049336A1
WO2001049336A1 PCT/IT1999/000428 IT9900428W WO0149336A1 WO 2001049336 A1 WO2001049336 A1 WO 2001049336A1 IT 9900428 W IT9900428 W IT 9900428W WO 0149336 A1 WO0149336 A1 WO 0149336A1
Authority
WO
WIPO (PCT)
Prior art keywords
acrylamide
bis
hydrogel
ethylene
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IT1999/000428
Other languages
French (fr)
Inventor
Vladislav Lopatine
Grigori Matiachvili
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PROGEN Srl
Original Assignee
PROGEN Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PROGEN Srl filed Critical PROGEN Srl
Priority to PCT/IT1999/000428 priority Critical patent/WO2001049336A1/en
Priority to AU20019/00A priority patent/AU2001900A/en
Publication of WO2001049336A1 publication Critical patent/WO2001049336A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52Hydrogels or hydrocolloids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/16Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds

Definitions

  • the invention relates to a composition and a method of producing a biologically compatible hydrogel on the basis of cross-linked copolymer of acrylamide with a linking agent, which can be used as medical purpose material, e.g.: for endoprosthetics by means of purposeful injection of hydrogel.
  • a linking agent which can be used as medical purpose material, e.g.: for endoprosthetics by means of purposeful injection of hydrogel.
  • hydrogel for plastics of soft facial tissue, mammal gland, penis, sural muscle, cords and other tissues fitting hydrogel consistence; as a filling agent for endoprostheses including mammal gland endopro- stheses; as medicine depot for protracted medication of tumors and abscesses (for example).
  • Acrylamide-based hydrogels can be used as such a material.
  • GB Patent No 21 14578 describes hydrogel on the basis of copolymer of acrylamid with methylene-bis-acrylamide as a linking agent assigned for lens manufacture. Said hydrogel containes 1 1 % wt of copolymer (with acrylamide to methylene-bis-acrylamide mass ratio 100:2,26) and 89 wt per cent of physio- logical salt solution.
  • Method of producing such a hydrogel described in the patent mentioned consists in copolymerization of acrylamide and methylene-bis-acrylamide as a linking agent in physiological salt solution in the presence of copolymerization initiators (tetramethylethylenediamine is one of them) with subsequent washing out of unreacted monomers from the end product. Copolymerization is conducted in a single stage at room temperature.
  • hydrogel thus obtained is unfit for soft tissue plastics because of its high consistence. Besides, due to a single stage process, this gel contains a lot of monomers and free radicals causing negative tissue response of organism.
  • Biocompatible hydrogel described in Claim EP No 742022 contains 3.5 to 9.0% wt of cross-linked copolymer of acrylamide with methylene-bis- acrylamide as a linking agent inaqueous medium.
  • Method of producing this hydrogel described in the Claim consists in acrylamide with methylene-bis-acrylamide copolymerization in inaqueous medium in the presence of peroxide initiators. Reaction mass is maintained at room temperature for 20 minutes for cross-linking a polymer. Copolymeriza- tion process in this case is also a single- stage one, mixture of persulphate and tetramethylethylenediaminebeing used as peroxide initiator of copolymerization. Apirogenic water or sodium chloride solution is taken as aqueous medium. Thus obtained hydrogel has inadequate degree of cross-linking due to low copolymeryzation process temperature and its single-stageness.
  • hydrogel containes unbound tetramethylethylenediamine molecules, free NH 2 radicals and acrylamide monomers in the amount of 1.0-1.2 ⁇ g per lg of gel (1.0-1.2 ppm).
  • Biocompatible hydrogel described in RU Patent No.2127129 contains
  • hydrogel does not contain unbound tetramethylethylene- diamine molecules, contains minimal quantity of free NH 2 radicals and acrylamide monomers in the amount of 0.6-0.8 ⁇ g per lg of gel (1.0-1.2 ppm). Furthermore, after implanting this material to a patient's body it shrinks to 12-15% of the initial level thus reducing cosmetic effect of plastic surgery. In some cases additional material injection is needed.
  • the task of dimi- nishing tissue response of an organism to the implant by reducing a number of free radicals and monomers in a hydrogel is also set.
  • biocompatible hydrogel for endoprosthetics containing cross-linked acrylamide copolymer with a linking agent and water contains mixture of N, N'- methylene-bis-acrylamide and N, N'-ethylene-bis-acrylamide, with acrylamide to N, N'-methylene-bis-acrylamide and N, N'-ethylene-bis- acrylamide mass ratio being 95.0-99.5 : 0.4-4,5 : 0.1-0,5 respectively.
  • Said hydrogel can contain as a linking agent a mixture of N, N'- methylene-bis-acrylamide, N, N'-ethylene-bis-acrylamide and ethylene-bis- (oxyethylene nitril)-tetracetic oxide or ethylene-bis-(oxyethylene nitril)tetracetic acid with mass ratio of acrylamide, N, N'-methylene-bis- acrylamide, N,N'-efhylene-bis-acrylamide and ethylene-bis-(oxyethylene nitril)-tetraacetic oxide or ethylene-bis-(oxyethylene nitril)-tetracetic acid being 95.0-99.5 : 0,4-4,5 : 0.08-0.4 : 0.02-0.1.
  • Said hydrogel has pH 4.5-7.5.
  • Cross-linked copolymer makes up 2.0 to 15% of the total hydrogel by weight.
  • Biocompatible hydrogel's distinctive feature is that it is obtained by copolymeryzation of acrylamide, N, N'-methylene-bis-acrylamide and N,N'- efhylene-bis-acrylamide with their mass ratio 95.0-99.5 : 0.4-4,5 : 0.1-0,5 respectively, in aqueous dispersing medium in the presence of peroxide polymerization initiator with reaction mass incubation at 20-90 °C for 2-24 hours and then at 115-130°C for 1-1.5 hours, with washing of semi-product in hot water at 90-100°C for 4-6 hours following the incubation at 20-90 °C.
  • Said hydrogel can be also produced by copolymerization of acrylamide with N, N'-methylene-bis-acrylamide, N,N'-ethylene-bis-acrylamide and ethylene-bis-(oxyethylene nitril)-tetracetic oxide with their mass ratio 95.0- 99.5 : 0,4-4,5 : 0.08-0.4 : 0.02-0.1 in aqueous medium in the presence of peroxide polymerization initiator with reaction mass incubation at 20-90°C for 2-24 hours and then at 1 15-130°C for 1 -1.5 hours, with semi-product wash- ing in hot water at 90-100°C for 4-6 hours which follows reaction mass incubation at 20-90°C.
  • the problems set are being solved by a method of producing biocompatible hydrogel by means of acrylamide and linking agent copoly- merization in aqueous dispersive medium in the presence of peroxide copolymerization initiator with reaction mass incubation promoting copolymer' s cross-linking in two stages.
  • the first stage is carried out at 20-90 °C for 2-24 hours, mixture of N, N'-methylene-bis-acrylamide and N, N'-ethylene-bis- acrylamide is taken as a linking agent, the second stage of incubation is held at 1 15-130°C for 1-1.5 h, the first incubation is followed by stock washing in hot water at 90-100°C during 4-6 h.
  • mass ratio of acrylamide to N, N'-methylene-bis-acrylamide and N, N'-ethylene-bis-acrylamide is 95.0- 99.5 : 0.4-4,5 : 0.1-0,5.
  • Method is also valid if mixture of N, N'-methylene-bis-acrylamide, N,N'-ethylene-bis-acrylamide and ethylene-bis-(oxyethylene nitril)-tetracetic oxide or ethylene-bis-(oxyethylene nitril)-tetracetic acid is used as a linking agent.
  • mass ratio of acrylamide, N, N'-methylene-bis- acrylamide, N,N'-ethylene-bis-acrylamide and ethylene-bis-(oxyethylene nitril)-tetracetic oxide or ethylene-bis-(oxyethylene nitril)-tetracetic acid is 95.0-99.5 : 0,4-4,5 : 0.08-0.4 : 0.02-0.1.
  • aqueous dispersive medium and total amount of acrylamide and linking agents must be taken, with initial water to monomers' mixture ratio being 85.0-98.0 : 2.0-15.0 mass parts.
  • Stock washing is carried out at mass ratio of semi-product to water 1 :8- 10.
  • Hydrogen peroxide and/or ammonium persulfate are taken as polymerization initiators, in the amount not exceeding 0.3% wt.
  • Twice-distilled apyrogenic water is taken as aqueous medium.
  • Hydrogel material on the basis of copolymer of acrylamide and linking agents is known to constitute a three-dimensional net, in this particular case, of cross-linked copolymer of acrylamid, N, N'-methylene-bis-acrylamide
  • methylene-bis-acrylamide and N, N'-ethylene-bis-acrylamide or cross- linked copolymer of acrylamid, N, N'-methylene-bis-acrylamide (methylene- bis-acrylamide), N, N'-ethylene-bis-acrylamide and ethylene-bis- (oxyethylene nitril)-tetracetic oxide or ethylene-bis-(oxyethylene nitril)- tetracetic acid.
  • Aqueous medium is retained within the net sells, cernain un- defined amount of unbound polymerization initiator is, in turn, retained within the aqueous medium.
  • Essense of invention consists in experimental selection of conditions for biocompatible hydrogel production, which allowed reducing amount of unbound amides, free NH 2 radicals and unsaturated double bonds.
  • linkage degree has been increased due to structural groups formation (HC- NH-CH), (-CO-NH-CR-O-R), (-CO-NH-NH-CO-), (H-COR-NH-CR-O-R), (-
  • Bromation level of thus produced hydrogel does not exceed 2.0 mg Br/1 and monomers content is not more than 0.4 ppm.
  • assessment of known hydrogel according to RU patent No. 2127129 shows bromation level of 3.0 mg Br/1 and monomers content of 0.6-0.8 ppm.
  • N,N'-methylene-bis-acrylamide C 7 H 10 N 2 O 2 , mol.wt - 154,16, white odourless crystal powder, melting point is 185 °C, produced by Sigma Co. (USA); N,N'- ethylene-bis-acrylamide produced by Aldrich Co. (USA);
  • Ammonium persulfate (NH 4 ) 2 S 2 O 8 , mol. wt - 228.19, flat colourless crystals; decomposition point is 120°C; produced by Sigma Co. (USA); All above-mentioned monomers must be fit for biological use and they must not need additional purification.
  • Aqueous solution of acrylamide and linking agents N, N'-methylene- bis-acrylamide and N, N'-ethylene-bis-acrylamide (taken in mass ratio 95 :
  • Polymerization initiators hydrogen peroxide in the amount of 0.1-0.3 % wt or ammonium persulfate in the amount of 0.0006-0.03 % wt or their mixture in any ratio in the amount not exceeding their total maximum are put to the solution.
  • hydrogen peroxide and ammonium persulfate amounts By varying hydrogen peroxide and ammonium persulfate amounts a material of desirable pH is obtained.
  • Finished reaction mass is filtrated through polymer bactericidal filters of F8273 brand with pore size of 0.45 mm CA/CN (producer - Sigma Co.(USA) and is incubated at 20-90°C for 2-24 h. After the incubation semi-product of gel-like appearance must be washed with hot water.
  • hydrogel characteristics have been measured: refractive index (by the technique described in "Physical Chemistry Workshop", M., 1974, pp.86-97); pH ( by the technique described in “Methodical Guideline For Sanita- tion Assessment of Rubber and Latex Goods of Medical Application", Moscow, 1988, pp.18, 19); bromation level (by the technique described in “Transactions of Guid- ing Materials On Toxicology Study of Polymer Materials and Goods of Medical Application", M. Ministry of Health of the USSR, 1987., pp.27-29); monomers content (by unpublished technique developed by the authors for evaluation of monomers content in water-containing polymers).
  • the claimed hydrogel has the following physicochemical characteristics: appearance - colorless gel; refractive index - 1.328-1.360; density - 0.9-1.2 g/cm 2 ; pH - 4.5-7.5; monomers content - ⁇ 0,4 ppm; bromation level - ⁇ 2.0 mg Br/1.
  • hydrogel extract did not display hemo- lytic effect 'in vitro' tests with isolated erythrocytes of rabbits. 0.04%o hemol- ysis occured with admissible level of 2%.
  • Test mouses autopsy indicated that tissue at gel injection point, regional glands, viscuses (liver, kidneys, and spleen) were within the physiological norm and control.
  • Tissue response to the claimed hydrogel implantation was studies dur- ing experimental and morphological and clinical morphological trials (see
  • Test was carried out on 160 male rats of August line, 200 g in weight and 10 dogs.
  • tissue blocks were fixed in 96° alcohol or neutral formalin and put in paraffin. Sections were colored with hematoxiline-eosin, picrofuxin by Van Gizon, silvering by Gomory to study fibrous components, with toluidine blue for acid glycosamineglycanes. PAS response to glycogen and glycoproteins as well as Brashe response to RNA were studied.
  • the capsulus In the capsular thickness as well as in the zone between the capsular and cellular tissue small fragments of hydrogel surrounded by macrophages and isolated giant multinucleous cells can be seen. 1 -3 months after the implantation the capsulus is still thin. It consists of mature conjunctive tissue with reduced number of fibroplasts, the remaining cells have lesser RNA content. There are hydrogel fragments in the transcapsular area which are resorbed by macrophages . Interior surface of the capsular is still coated with macrophages .
  • Tissue response at later terms was studied by subcutaneous implantation of gel to dogs.
  • a narrow lysis zone of the hydrogel can be seen.
  • the hydrogel is resorbed by macrophages and germinated with fibroplast bars in that zone.
  • Signs of lime sediments in the hydrogel can be found neither in dogs nor in rats.
  • Dystrophic cell changes in tissue surrounding the implant which could indicate toxic effect of the hydrogel, are not found.
  • hydrogel remained mostly homogeneous and conjunctive tissue germinated only near the capsular.
  • tissue response to the gel is feebly marked.
  • "Old" fibros capsular is in backward development in nearly all parts.
  • the implant is surrounded by a thin conjunctive tissue capsular having no interior myofibroplastic layer which takes place in case of silicone prosthesis.
  • small lympho-macrophagal infiltrates without inflammatory neutrophilic response can be seen in a "new" capsular.
  • Capsular's vasa are not numerous; there are no dystrophic changes and lime salt deposites in the capsular.
  • a superficial germination of thin conjunctive tissue bars (fibroplasts, macrophags and thin immature collagen fibers) into the hydrogel can be seen in a vicinity of the capsular.
  • Some macrophages have a big foamy cytoplasm
  • hydrogel It is significant that there was no deep invasion of macrophages and microphages into the hydrogel. It proves its stability to resorption in organ- ism. At the same time hydrogel does not reduce functional activity of cells and does not cause their dystrophy. This proves lack of migration of toxic substanses from gel to tissue. There is no calcification of hydrogel and surrounding tissues.
  • the biologically compatible hydrogel claimed causes no tissue response, no organism sensitization, it is not mutagenic, it causes no dystrophic and necrotic changes and can be used for endoprosthetics and contour soft tissue plastics.
  • hydrogel 19 g of acrylamide, 0.9 g of N,N' -methylene-bis- acrylamide and 0.1 g of N,N'-ethylene-bis-acrylamide suitable for biological application dissolved in 400 ml of twice-distilled apyrogenic water with a pH of 5.6. 0.04 g of ammonium persufate and 2 ml of 30% hydrogen peroxide were added to the solution.
  • the mixture obtained was filtrated through polymer bactericidal filter of F8273 brand with pore size 0.45 mm CA/CN (producer - Sigma Co. (USA) and placed in the vessel which was put to a water bath for incubation at 30 °C for 22 hours.
  • the gel like semi-product was washed in hot water with water to gel ratio 10: 1 at temperature of 90 °C for 4 hours and was further incubated for 1 hour at temperature not exceeding 125 °C.
  • the hydrogel obtained was sterilised by autoclaving (at temperature of
  • Bromation level - 0.1 (mg Br per 1L);
  • the hydrogel produced was injected to a female patient L-ya, aged 55, to replace a silicone prosthesis which had been used for primary mammaplasty 8 years before and caused coarse fibrosis of both mammals.
  • the patient was being seen for 8 months' post-operative period with monthly examinations. Fibrosis recurrence was not detected. Positive result was obtained: mammals' shape and size fit patient's constitution, their elasticity was typical for tissue of healthy mammal.
  • hydrogel 24.5 g of acrylamide, 0.375 g of N,N' -methylene- bis-acrylamide, 0.1 g of N,N'-ethylene-bis-acrylamide and 0.025 g of ethylene-bis-(oxyethylene nitril)-tetracetic oxide or ethylene-bis-
  • the hydrogel obtained was sterilised as described in example 1.
  • the produced material had the following physicochemical characteristics:
  • hydrogel 77.6 g of acrylamide, 2.08 g of N,N'-methylene- bis-acrylamide and 0.32 g of N,N'-ethylene-bis-acrylamide dissolved in 1000 ml of twice-distilled apyrogenic water with a pH of 5.6. Then 0.03 g of ammonium persufate was added to the solution. The mixture obtained was fil- trated as described in example 1 and put to incubation at 60 °C for 12 hours.
  • the gel was washed in hot water at 100°C for 4.5 hours and was further incubated for 1.5 hours at temperature of 120°C.
  • the hydrogel obtained was sterilised as described in example 1.
  • Bromation level - 0.05 (mg Br per 1L).
  • the hydrogel obtained was used for sural muscle plasty.
  • 150 g of hy- drogel was implanted into each sural muscle of a patient S., aged 47. The patient was being seen for 12 months' post-operative period with periodic examinations of every 3 months. Inflammatory and allergic effects were not detected. Desirable cosmetic effect was obtained.
  • hydrogel 23.75 g of acrylamide, 1.075 g of N, N'- methylene-bis-acrylamide, 0.045 g of N,N'-ethylene-bis-acrylamide and 0.005 g of ethylene-bis-(oxyethylene nitril)-tetracetic oxide or ethylene-bis- (oxyethylene nitril)-tetracetic acid dissolved in 400 ml of twice-distilled apyrogenic water with a pH of 5.6. Then 0.02 g of ammonium persufate and
  • the hydrogel produced was injected to a female patient L-ya, aged 26, to replace a silicone prosthesis which had been used for primary mammaplasty 3 years before and caused fibrosis of both mammals 7 months after the operation.
  • Surgery was performed to remove silicone prosthesis with open capsulotomy and delayed injection of 180 g of hydrogel to each mammal. 3 months later another 100 g of the same hydrogel was injected to each mammal.
  • the patient was being seen for 7 months' post-operative period with once-every-two-months examinations. Fibrosis recurrence was not detected.
  • mammals' shape and size fit patient's constitu- tion their elasticity was typical for tissue of healthy mammal. A desirable cosmetic effect was obtained.
  • examples given prove possibility of producing biocompatible hydrogel and of using it for plastics of soft tissues.
  • a hydrogel can also be used as a filling agent for endoprostheses comprising a cover and a filling agent.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)

Abstract

The present invention relates to a composition and a method of producing a biologically compatible hydrogel for endoprosthetics containing cross-linked copolymer of acrylamide with a linking agent and water wherein said linking agent can be a mixture of acrylamide, N, N'-methylene-bis-acrylamide, N, N'-ethylene-bis-acrylamide, ethylene-bis-(oxyethylene nitril)-tetracetic oxide or ethylene-bis-(oxyethylene nitril)-tetracetic acid.

Description

Description
BIOCOMPATIBLE HYDROGEL AND METHOD OF ITS PRODUCTION
Technical Field
The invention relates to a composition and a method of producing a biologically compatible hydrogel on the basis of cross-linked copolymer of acrylamide with a linking agent, which can be used as medical purpose material, e.g.: for endoprosthetics by means of purposeful injection of hydrogel. For plastics of soft facial tissue, mammal gland, penis, sural muscle, cords and other tissues fitting hydrogel consistence; as a filling agent for endoprostheses including mammal gland endopro- stheses; as medicine depot for protracted medication of tumors and abscesses (for example).
Background Art
The task of obtaining synthetic materials for soft tissue (muscles and subcutaneous tissue) substitutions is essential for medical practice. These materials must be relatively cheap and easy to produce. They must have necessary physicochemical properties (such as certain consistance and chemical inertness, capability to shrink and swell after being placed into the body) as well as biological properties (biological inertness, lack of rejection or any other tissue response). Besides, a material must have a convenient form for muscular tissue injection with a minimal injury of patient's body.
Acrylamide-based hydrogels can be used as such a material. GB Patent No 21 14578 describes hydrogel on the basis of copolymer of acrylamid with methylene-bis-acrylamide as a linking agent assigned for lens manufacture. Said hydrogel containes 1 1 % wt of copolymer (with acrylamide to methylene-bis-acrylamide mass ratio 100:2,26) and 89 wt per cent of physio- logical salt solution.
Method of producing such a hydrogel described in the patent mentioned (GB No. 21 14578) consists in copolymerization of acrylamide and methylene-bis-acrylamide as a linking agent in physiological salt solution in the presence of copolymerization initiators (tetramethylethylenediamine is one of them) with subsequent washing out of unreacted monomers from the end product. Copolymerization is conducted in a single stage at room temperature.
However, hydrogel thus obtained is unfit for soft tissue plastics because of its high consistence. Besides, due to a single stage process, this gel contains a lot of monomers and free radicals causing negative tissue response of organism.
Biocompatible hydrogel described in Claim EP No 742022 contains 3.5 to 9.0% wt of cross-linked copolymer of acrylamide with methylene-bis- acrylamide as a linking agent inaqueous medium.
Method of producing this hydrogel described in the Claim consists in acrylamide with methylene-bis-acrylamide copolymerization in inaqueous medium in the presence of peroxide initiators. Reaction mass is maintained at room temperature for 20 minutes for cross-linking a polymer. Copolymeriza- tion process in this case is also a single- stage one, mixture of persulphate and tetramethylethylenediaminebeing used as peroxide initiator of copolymerization. Apirogenic water or sodium chloride solution is taken as aqueous medium. Thus obtained hydrogel has inadequate degree of cross-linking due to low copolymeryzation process temperature and its single-stageness. It re- suits in a rapid intergrowth of conjunctive tissue to the implanted gel and in its rapid shrinkage and resorption (see A.B.Shekhter et al "Injectible hydro- philic polyacrylamide gel Formacryl and tissue response to its Implantation" Annals of Anaplastic, Reconstructive and Aesthetic Surgery, 1997, No.2, p.19). Besides, thus obtained hydrogel containes unbound tetramethylethylenediamine molecules, free NH2 radicals and acrylamide monomers in the amount of 1.0-1.2 μg per lg of gel (1.0-1.2 ppm). This can cause active asep- tic inflammatory reaction at an early stage of gel implanting (see A.B.Shekhter et al "Injectible hydrophilic polyacrylamide gel Formacryl and tissue response to its Implantation", Annals of Anaplastic, Reconstructive and Aesthetic Surgery, 1997, No.2, p.19). Biocompatible hydrogel described in RU Patent No.2127129 contains
1.0 to 8.0 %wt of cross-linked copolymer of acrylamide with methylene-bis- acrylamide in aqueous medium. Method of producing this hydrogel is described in the above mentioned patent RU No.2127129. It consists in copolymerization of acrylamide with methylene-bis-acrylamide (as a linking agent) in aqueous dispersing medium in the presence of peroxide initiator. Water subjected to electrolysis with pH of 9.0-9.5 is taken as aqueous dispersing medium. In this case copolymer' s linking is carried out through the reaction blend incubation in two stages: at temperatures 20-90 °C for 2-24 hours and then at 100-105 °C for 2-4 hours. Thus produced hydrogel does not contain unbound tetramethylethylene- diamine molecules, contains minimal quantity of free NH2 radicals and acrylamide monomers in the amount of 0.6-0.8 μg per lg of gel (1.0-1.2 ppm). Furthermore, after implanting this material to a patient's body it shrinks to 12-15% of the initial level thus reducing cosmetic effect of plastic surgery. In some cases additional material injection is needed.
Disclosure of Invention
An object of the present invention is to reduce resorption and shrinkage levels of a biocompatible hydrogel containing cross-linked acrylamide copolymer after its implanting to a patient's body by increasing monomers' cross- linking characterized by the presence of the following structural groups: (HC-NH-CH), (-CO-NH-CR-O-R), (-CO-NH-NH-CO-), (H-COR-NH-CR-O- R), (-CONH-R-NH-CO), where R = CH3, CH2, NH2, C2H5. The task of dimi- nishing tissue response of an organism to the implant by reducing a number of free radicals and monomers in a hydrogel is also set.
The tasks set have been solved as follows: biocompatible hydrogel for endoprosthetics containing cross-linked acrylamide copolymer with a linking agent and water according to the invention contains mixture of N, N'- methylene-bis-acrylamide and N, N'-ethylene-bis-acrylamide, with acrylamide to N, N'-methylene-bis-acrylamide and N, N'-ethylene-bis- acrylamide mass ratio being 95.0-99.5 : 0.4-4,5 : 0.1-0,5 respectively.
Said hydrogel can contain as a linking agent a mixture of N, N'- methylene-bis-acrylamide, N, N'-ethylene-bis-acrylamide and ethylene-bis- (oxyethylene nitril)-tetracetic oxide or ethylene-bis-(oxyethylene nitril)tetracetic acid with mass ratio of acrylamide, N, N'-methylene-bis- acrylamide, N,N'-efhylene-bis-acrylamide and ethylene-bis-(oxyethylene nitril)-tetraacetic oxide or ethylene-bis-(oxyethylene nitril)-tetracetic acid being 95.0-99.5 : 0,4-4,5 : 0.08-0.4 : 0.02-0.1. Said hydrogel has pH 4.5-7.5.
Cross-linked copolymer makes up 2.0 to 15% of the total hydrogel by weight.
Hydrogel contains twice-distilled apyrogenic water as aqueous medium. Additional feature of hydrogel is that the cross-linked copolymer has structural groups (HC-NH-CH), (-CO-NH-CR-O-R), (-CO-NH-NH-CO-), (H- COR-NH-CR-O-R), (-CONH-R-NH-CO), where R = CH3, CH2, NH2, C2H5. Biocompatible hydrogel's distinctive feature is that it is obtained by copolymeryzation of acrylamide, N, N'-methylene-bis-acrylamide and N,N'- efhylene-bis-acrylamide with their mass ratio 95.0-99.5 : 0.4-4,5 : 0.1-0,5 respectively, in aqueous dispersing medium in the presence of peroxide polymerization initiator with reaction mass incubation at 20-90 °C for 2-24 hours and then at 115-130°C for 1-1.5 hours, with washing of semi-product in hot water at 90-100°C for 4-6 hours following the incubation at 20-90 °C.
Said hydrogel can be also produced by copolymerization of acrylamide with N, N'-methylene-bis-acrylamide, N,N'-ethylene-bis-acrylamide and ethylene-bis-(oxyethylene nitril)-tetracetic oxide with their mass ratio 95.0- 99.5 : 0,4-4,5 : 0.08-0.4 : 0.02-0.1 in aqueous medium in the presence of peroxide polymerization initiator with reaction mass incubation at 20-90°C for 2-24 hours and then at 1 15-130°C for 1 -1.5 hours, with semi-product wash- ing in hot water at 90-100°C for 4-6 hours which follows reaction mass incubation at 20-90°C.
The problems set are being solved by a method of producing biocompatible hydrogel by means of acrylamide and linking agent copoly- merization in aqueous dispersive medium in the presence of peroxide copolymerization initiator with reaction mass incubation promoting copolymer' s cross-linking in two stages. The first stage is carried out at 20-90 °C for 2-24 hours, mixture of N, N'-methylene-bis-acrylamide and N, N'-ethylene-bis- acrylamide is taken as a linking agent, the second stage of incubation is held at 1 15-130°C for 1-1.5 h, the first incubation is followed by stock washing in hot water at 90-100°C during 4-6 h. In this case, mass ratio of acrylamide to N, N'-methylene-bis-acrylamide and N, N'-ethylene-bis-acrylamide is 95.0- 99.5 : 0.4-4,5 : 0.1-0,5.
Method is also valid if mixture of N, N'-methylene-bis-acrylamide, N,N'-ethylene-bis-acrylamide and ethylene-bis-(oxyethylene nitril)-tetracetic oxide or ethylene-bis-(oxyethylene nitril)-tetracetic acid is used as a linking agent. In this case, mass ratio of acrylamide, N, N'-methylene-bis- acrylamide, N,N'-ethylene-bis-acrylamide and ethylene-bis-(oxyethylene nitril)-tetracetic oxide or ethylene-bis-(oxyethylene nitril)-tetracetic acid is 95.0-99.5 : 0,4-4,5 : 0.08-0.4 : 0.02-0.1.
For method's implementation aqueous dispersive medium and total amount of acrylamide and linking agents must be taken, with initial water to monomers' mixture ratio being 85.0-98.0 : 2.0-15.0 mass parts.
Stock washing is carried out at mass ratio of semi-product to water 1 :8- 10.
Hydrogen peroxide and/or ammonium persulfate are taken as polymerization initiators, in the amount not exceeding 0.3% wt.
Twice-distilled apyrogenic water is taken as aqueous medium.
Hydrogel material on the basis of copolymer of acrylamide and linking agents is known to constitute a three-dimensional net, in this particular case, of cross-linked copolymer of acrylamid, N, N'-methylene-bis-acrylamide
(methylene-bis-acrylamide) and N, N'-ethylene-bis-acrylamide or cross- linked copolymer of acrylamid, N, N'-methylene-bis-acrylamide (methylene- bis-acrylamide), N, N'-ethylene-bis-acrylamide and ethylene-bis- (oxyethylene nitril)-tetracetic oxide or ethylene-bis-(oxyethylene nitril)- tetracetic acid. Aqueous medium is retained within the net sells, cernain un- defined amount of unbound polymerization initiator is, in turn, retained within the aqueous medium. Another undefined amount of polymerization initiator directly incorporates into copolymer' s structure (see M.N.Savitskaya, Y.D.Kholodova "Polyacrilamide", Technika, 1969, p.103) or is washed off the gel if washing occurs. In addition, biologically active properties of such a gel to a considerable degree depend on cancellous structure of polymer, which, in turn, depends on polymer's synthesis conditions viz input components ratio, qualitative content of copolymerization initiators, which, by means of chemical and hydrbgen bonds incorporate into copolymer's structure (through NH, CH, COOH, NH2, CH2 groups) and on temperature range of polymerization.
Essense of invention consists in experimental selection of conditions for biocompatible hydrogel production, which allowed reducing amount of unbound amides, free NH2 radicals and unsaturated double bonds. In addition, linkage degree has been increased due to structural groups formation (HC- NH-CH), (-CO-NH-CR-O-R), (-CO-NH-NH-CO-), (H-COR-NH-CR-O-R), (-
CONH-R-NH-CO), where R = CH3, CH2, NH2, C2H5, and due to increasing amounts of cross-linking N-N bonds. All this allowed to ensure material's resistance to shrinkage, its high elasticity and tenacity, which, in turn, ensure high form stability of material at implanting. It was experimentally proved during hydrogel implanting to animals, rats and dogs in particular, with subsequent test of solid residual of hydrogel after 1, 3 and 6 month' residence of implant in animal bodies. Even after 6 month' residence loss of aqueous phase was found not to exceed 5% of its initial content in implant. Whereas loss of aqueous phase in implant obtained by method of RU patent No. 2127129 amounted to 10% at similar conditions.
Indirect evidence on the amount of unbound NH2 radicals, monomers and unsaturated double bonds can be obtained by bromation level, IR spec- troscopy and chromatomass- spectrometry data.
Bromation level of thus produced hydrogel does not exceed 2.0 mg Br/1 and monomers content is not more than 0.4 ppm. Whereas assessment of known hydrogel according to RU patent No. 2127129 shows bromation level of 3.0 mg Br/1 and monomers content of 0.6-0.8 ppm.
Hydrogel, IR spectrum and extract chromatogram, contains 96% of water phase and 4% of copolymer having 96 mass parts of acrylamide, 3.6 mass parts of N, N'-methylene-bis-acrylamide and 0.4 mass parts of N,N'- ethylene-bis-acrylamide in its content. It's pH=4.6, bromation level - 0.15 mg Br/1 and it was obtained at incubation of initial blend in the presence of hydrogen peroxide and ammonium persulfate with 0.3% wt total at 60°C for 12 h and then at 120°C for one more hour.
As the spectrum shows, it lacks bands of 1620 cm'1 corresponding to deformation vibrations of NH2 radicals, as well as 3200 cm"1 and 3600 cm"1, corresponding to stretching vibrations of these radicals. It indicates that free
NH2 radicals content in polymer structure does not exceed 1% of all functional groups. As the chromatogram shows monomers content does not exceed 0,4 ppm.
Following substances are used for the method's implementation: Acrylamide: C3 H5 NO, mol. wt is 71.08, white odourless crystal powder, melting point is 84,5 °C, produced by Sigma Co. (USA);
N,N'-methylene-bis-acrylamide: C7 H10 N2 O2, mol.wt - 154,16, white odourless crystal powder, melting point is 185 °C, produced by Sigma Co. (USA); N,N'- ethylene-bis-acrylamide produced by Aldrich Co. (USA);
Ethylene-bis-(oxyethylene nitril)-tetracetic oxide or ethylene-bis- (oxyethylene nitril)-tetracetic acid produced by Aldrich Co. (USA);
Ammonium persulfate: (NH4)2 S2 O8, mol. wt - 228.19, flat colourless crystals; decomposition point is 120°C; produced by Sigma Co. (USA); All above-mentioned monomers must be fit for biological use and they must not need additional purification.
Twice-distilled apyrogenic water must be used (pH=5.6). A method is carried out as follows:
Twice-distilled apyrogenic water (pH=5.6) is used for reaction mass preparation.
Aqueous solution of acrylamide and linking agents: N, N'-methylene- bis-acrylamide and N, N'-ethylene-bis-acrylamide (taken in mass ratio 95 :
0.4 : 0,1 e.g.) or N, N'-methylene-bis-acrylamide, N, N'-ethylene-bis- acrylamide and ethylene-bis-(oxyethylene nitril)-tetracetic oxide or ethylene- bis-(oxyethylene nitril)-tetracetic acid (taken in mass ratio 95 : 0.4 : 0,08 : 0.02 e.g.) is to be prepared, total amount of initial monomers in the solution is 2.0-15.0%) ( hydrogel of different consistency and elasticity can be obtained varying amount of initial monomers in the mass)
Polymerization initiators: hydrogen peroxide in the amount of 0.1-0.3 % wt or ammonium persulfate in the amount of 0.0006-0.03 % wt or their mixture in any ratio in the amount not exceeding their total maximum are put to the solution. By varying hydrogen peroxide and ammonium persulfate amounts a material of desirable pH is obtained. Finished reaction mass is filtrated through polymer bactericidal filters of F8273 brand with pore size of 0.45 mm CA/CN (producer - Sigma Co.(USA) and is incubated at 20-90°C for 2-24 h. After the incubation semi-product of gel-like appearance must be washed with hot water. For that purpose it is placed for 4-6 h to a vessel with 90-100°C water, gel to water volume ratio being 1 : 8-10. Then the second stage of incubation at 1 15-130°C for 1.0-1.5 h is held. The gel obtained is packed in bottles of desirable volume and sterilised by autoclaving (at 120°C, p=1.2 atm) within 20 minutes.
The following hydrogel characteristics have been measured: refractive index (by the technique described in "Physical Chemistry Workshop", M., 1974, pp.86-97); pH ( by the technique described in "Methodical Guideline For Sanita- tion Assessment of Rubber and Latex Goods of Medical Application", Moscow, 1988, pp.18, 19); bromation level (by the technique described in "Transactions of Guid- ing Materials On Toxicology Study of Polymer Materials and Goods of Medical Application", M. Ministry of Health of the USSR, 1987., pp.27-29); monomers content (by unpublished technique developed by the authors for evaluation of monomers content in water-containing polymers). The claimed hydrogel has the following physicochemical characteristics: appearance - colorless gel; refractive index - 1.328-1.360; density - 0.9-1.2 g/cm2; pH - 4.5-7.5; monomers content - < 0,4 ppm; bromation level - < 2.0 mg Br/1.
Sanitary, chemical, toxicological and pathomorphological tests of the claimed biocompatible hydrogel were performed. Tests were carried out in accordance with ISO 10993 Standard "Evaluation Of Biological Effect Of Medical Goods", "Transactions of Guiding Materials On Toxicology Study of Polymer Materials and Goods of Medical Application", "Admissible Quantities Of Migrations OF Chemical Substancies Emissions From Polymers And Other Materials In Contact with Foodstaffs And Methods Of Their Evaluation" SanPin 42-122-42-40-86.
Sanitary and chemical tests showed that: pH of water extract of hydrogel differed from a control test by 0.33, admissible difference being ±1; migration of metals - Cu, Fe, Ni, Zn, Al, Ti, Ag to a hydrogel water extract, determined by atomic absorptive analysis was not indicated within the method's sensitivity value (0.02; 0.05; 0.05, 0.02; 0.005; 0.04 mg/1 correspondigly), which is substantially lower than admissible levels for foodstaffs and drinking water; sodium migration was 0.12 mg/1, admissible level in drinking water being 200 mg/1;
Toxicological tests showed that hydrogel extract did not display hemo- lytic effect 'in vitro' tests with isolated erythrocytes of rabbits. 0.04%o hemol- ysis occured with admissible level of 2%.
Parenteral hydrogel injection (50 ml per 1 kg of body weight) in acute test with white mouses resulted in no deaths of animals or clinical intoxication signs: no difference occurred between behaviour, feeding up and hair condition of tested and control mouses.
Test mouses autopsy indicated that tissue at gel injection point, regional glands, viscuses (liver, kidneys, and spleen) were within the physiological norm and control.
No statistically reliable difference was found in body weight dynamics, clinical biochemical blood tests and viscus coefficients of tested and controlled animals after subcutaneous gel implanting for 2.5 months.
No sensitizing effect of gel was indicated during immunological diagnostic mast cell degranulation reaction (MCDR).
Microcore test on marrow substancies indicated no mutagenic effect of the hydrogel. Histologic study of hydrogel implanting area and viscuses
(liver, kidneys, spleen, testicles) showed feebly marked signs of tissue response to hydrogel only during first days after implanting and lack of dys- trophic and necrotic changes in organs.
Tissue response to the claimed hydrogel implantation was studies dur- ing experimental and morphological and clinical morphological trials (see
A.B.Shekhter et al "Injectible hydrophilic polyacrylamide gel Formacryl and tissue response to its Implantation", Annals of Anaplastic, Reconstructive and
Aesthetic Surgery, 1997, No.2, p.11-21).
For these tests hydrogel samples were taken containing 96% of aqueous phase and 4% of copolymer with mass ratio of acrylamid, N, N'-methylene- bis-acrylamide (methylene-bis-acrylamide) and N, N'-ethylene-bis- acrylamide (pH=4.6) of 96 : 3.6 : 0.4, with bromation level of 0.15 mg Br/1. Hydrogel was obtained by incubation of initial mass in the presence of hydrogen peroxide and ammonium persulfate in the total amount of 0.3%) wt at 60°C for 12 h and then at 120°C for one more hour, with stock washing in hot water (t=90°C) for 4 h.
Test was carried out on 160 male rats of August line, 200 g in weight and 10 dogs.
1 ml of hydrogel was iniected to a rat subcutaneously (intramuscular). Terms of morphological studies were 3, 7, 14, 30 and 90 days.
Long periods of implantation (6-12 months) were studied on dogs after subcutaneous injection of 15 ml of hydrogel.
Clinical morphological studies of tissues after the implantation of the same gel to 5 patients were carried out: 1 month after subcutaneous implantation to a face area, 1.5 and 3.5 months after intramuscular implantation to shanks and 6 and 6.5 months after implantation for increasing mammaplasty by filling a fibrous capsular with a gel after silicon prosthesis removal.
For histology studies tissue blocks were fixed in 96° alcohol or neutral formalin and put in paraffin. Sections were colored with hematoxiline-eosin, picrofuxin by Van Gizon, silvering by Gomory to study fibrous components, with toluidine blue for acid glycosamineglycanes. PAS response to glycogen and glycoproteins as well as Brashe response to RNA were studied.
Morphological study of body tissue response to the implantation of the claimed hydrogel carried out on rats showed that it was minimal. It was limited at early stages (3-7 days after the implantation) to a weak lympho- macrophagal infiltration with isolated neutrophils and flabby tissue edema, which indicated a minimum inflammatory response. After 3 days' proliferation of fibroblasts in a narrow zone surrounding implant occured, and a very thin conjunctive tissue capsular was formed by the 7th day which consisted of fibroblasts and thin collagen fibers. This capsular was covered inside with nearly perpetual macrophage layer adjoining the implant. After 14 days the capsular get more distinctive but still remained thin and flocculent. In the capsular thickness as well as in the zone between the capsular and cellular tissue small fragments of hydrogel surrounded by macrophages and isolated giant multinucleous cells can be seen. 1 -3 months after the implantation the capsulus is still thin. It consists of mature conjunctive tissue with reduced number of fibroplasts, the remaining cells have lesser RNA content. There are hydrogel fragments in the transcapsular area which are resorbed by macrophages . Interior surface of the capsular is still coated with macrophages .
Tissue response at later terms (6, 9 and 12 months) was studied by subcutaneous implantation of gel to dogs. In a vicinity of a very thin and dense conjunctive tissue capsular a narrow lysis zone of the hydrogel can be seen. The hydrogel is resorbed by macrophages and germinated with fibroplast bars in that zone. There was no deep infiltration of cells into hydrogel neither in dog nor in rat experiments and that is the cause of its durable stability. Signs of lime sediments in the hydrogel can be found neither in dogs nor in rats. Dystrophic cell changes in tissue surrounding the implant, which could indicate toxic effect of the hydrogel, are not found.
Clinic and morphology observations held 1 month after injection of 90 ml of hydrogel for dermatensy of scin-fatty shred on a face with the purpose of further cicatrix plastics showed that a very thin and flocculent conjunctive tissue capsule is formed on a hydrogel - tissue boundary. That capsule con- sists of just a few layers of collagen fibres and fibroplasts. Cell lympomacrophagal infiltration is minimal. Tissue vacuoles replacing resorbed gel can be seen in some spots outside the capsule. Feebly marked macrophagal and giant cell response is indicated there. Similar results were obtained in two cases of observations of contour plastics of shin soft tissue by the implantation of the claimed hydrogel. 1.5 and 3.5 months after the implantation hydrogel remained mostly homogeneous and conjunctive tissue germinated only near the capsular. In morphological study of biopsy taken 6.5 months after injection of 200 ml of the claimed hydrogel replacing sili- cone prosthesis in residuary fibros capsular cavity. The tissue response to the gel is feebly marked. "Old" fibros capsular is in backward development in nearly all parts. The implant is surrounded by a thin conjunctive tissue capsular having no interior myofibroplastic layer which takes place in case of silicone prosthesis. In some spots, small lympho-macrophagal infiltrates without inflammatory neutrophilic response can be seen in a "new" capsular. Capsular's vasa are not numerous; there are no dystrophic changes and lime salt deposites in the capsular.
A superficial germination of thin conjunctive tissue bars (fibroplasts, macrophags and thin immature collagen fibers) into the hydrogel can be seen in a vicinity of the capsular. Some macrophages have a big foamy cytoplasm
(active phagocytosis). Conjunctive tissue bars divide gel around the capsular into fragments. Gel retained homogeneity in some fragments and obtained fine-meshed or fibrillar structure in some other fragments. Only isolated cell elements (macrophages) are seen inside remote from the capsular gel's parts.
Histology study results obtained in a long-term dynamics on animals as well as on biopsy clinic material indicate high biological compatibility of the hydrogel claimed. A very weak and rapidly disappearing inflammatory re- sponse was observed short time after the injection of claimed hydrogel into a body, fibroblastic response was weak and slow, late formation of a capsula took place and it remained thin for the whole period of observation.
It is significant that there was no deep invasion of macrophages and microphages into the hydrogel. It proves its stability to resorption in organ- ism. At the same time hydrogel does not reduce functional activity of cells and does not cause their dystrophy. This proves lack of migration of toxic substanses from gel to tissue. There is no calcification of hydrogel and surrounding tissues.
Thus, the biologically compatible hydrogel claimed causes no tissue response, no organism sensitization, it is not mutagenic, it causes no dystrophic and necrotic changes and can be used for endoprosthetics and contour soft tissue plastics.
Here are examples of claimed method's realisation and use of hydrogel produced for soft tissue plastics. EXAMPLE 1.
To obtain hydrogel, 19 g of acrylamide, 0.9 g of N,N' -methylene-bis- acrylamide and 0.1 g of N,N'-ethylene-bis-acrylamide suitable for biological application dissolved in 400 ml of twice-distilled apyrogenic water with a pH of 5.6. 0.04 g of ammonium persufate and 2 ml of 30% hydrogen peroxide were added to the solution. The mixture obtained was filtrated through polymer bactericidal filter of F8273 brand with pore size 0.45 mm CA/CN (producer - Sigma Co. (USA) and placed in the vessel which was put to a water bath for incubation at 30 °C for 22 hours. The gel like semi-product was washed in hot water with water to gel ratio 10: 1 at temperature of 90 °C for 4 hours and was further incubated for 1 hour at temperature not exceeding 125 °C. The hydrogel obtained was sterilised by autoclaving (at temperature of
120°C, pressure of 1.2 atm) within 20 minutes.
The produced material had the following physicochemical characteristics:
Appearance - colorless gel; Refractive index - 1.348; pH - 5,4;
Density - 1.0 g/cm2;
Monomers content - 0.2 ppm;
Bromation level - 0.1 (mg Br per 1L); The hydrogel produced was injected to a female patient L-ya, aged 55, to replace a silicone prosthesis which had been used for primary mammaplasty 8 years before and caused coarse fibrosis of both mammals. The patient was being seen for 8 months' post-operative period with monthly examinations. Fibrosis recurrence was not detected. Positive result was obtained: mammals' shape and size fit patient's constitution, their elasticity was typical for tissue of healthy mammal.
EXAMPLE 2
To obtain hydrogel, 24.5 g of acrylamide, 0.375 g of N,N' -methylene- bis-acrylamide, 0.1 g of N,N'-ethylene-bis-acrylamide and 0.025 g of ethylene-bis-(oxyethylene nitril)-tetracetic oxide or ethylene-bis-
(oxyethylene nitril)-tetracetic acid dissolved in 1000 ml of twice-distilled apyrogenic water with a pH of 5.6. 2.5 g of ammonium persufate was added to the solution. The mixture obtained was filtrated as described in example 1 and put to incubation at 80°C for 2 hours. The gel was washed in hot water at of 100°C for 5.5 hours and was further incubated for 1.5 hours at temperature of 125 °C.
The hydrogel obtained was sterilised as described in example 1. The produced material had the following physicochemical characteristics:
Appearance - colorless gel;
Refractive index - 1.344; pH - 6,8;
Density - 1.0 g/cm2;
Acrylamide monomers content - absence;
Monomers content - 0.32 ppm;
Bromation level - 0.15 (mg Br per 1L). The hydrogel obtained was used for subcutaneous tissue plasty for face wrinkles removal. The hydrogel was injected to a female patient S., aged 47. The patient was being seen for 12 months' post-operative period with periodic examinations of every 3 months. Inflammatory and allergic effects were not detected. Desirable cosmetic effect was obtained. EXAMPLE 3
To obtain hydrogel, 77.6 g of acrylamide, 2.08 g of N,N'-methylene- bis-acrylamide and 0.32 g of N,N'-ethylene-bis-acrylamide dissolved in 1000 ml of twice-distilled apyrogenic water with a pH of 5.6. Then 0.03 g of ammonium persufate was added to the solution. The mixture obtained was fil- trated as described in example 1 and put to incubation at 60 °C for 12 hours.
The gel was washed in hot water at 100°C for 4.5 hours and was further incubated for 1.5 hours at temperature of 120°C.
The hydrogel obtained was sterilised as described in example 1.
The produced material had the following physicochemical characteris- tics:
Appearance - colorless gel;
Refractive index - 1.352; pH - 5.2;
Density - 1.2 g/cm2; Monomers content - 0.2 ppm;
Bromation level - 0.05 (mg Br per 1L).
The hydrogel obtained was used for sural muscle plasty. 150 g of hy- drogel was implanted into each sural muscle of a patient S., aged 47. The patient was being seen for 12 months' post-operative period with periodic examinations of every 3 months. Inflammatory and allergic effects were not detected. Desirable cosmetic effect was obtained. EXAMPLE 4
To obtain hydrogel, 23.75 g of acrylamide, 1.075 g of N, N'- methylene-bis-acrylamide, 0.045 g of N,N'-ethylene-bis-acrylamide and 0.005 g of ethylene-bis-(oxyethylene nitril)-tetracetic oxide or ethylene-bis- (oxyethylene nitril)-tetracetic acid dissolved in 400 ml of twice-distilled apyrogenic water with a pH of 5.6. Then 0.02 g of ammonium persufate and
1 ml Of 30%) hydrogen peroxide was added to the solution. The mixture obtained was filtrated as described in example 1 and put to incubation at 50 °C for 16 hours. The gel was washed in hot water at of 100°C for 4.0 hours and was further incubated for 1.5 hours at temperature of 130°C. The hydrogel obtained was sterilised as described in example 1.
The produced material had the following physicochemical characteristics:
Appearance - colorless gel;
Refractive index - 1.348; pH - 4.8;
Density - 1.0 g/cm2;
Monomers content - 0.3 ppm;
Bromation level - 0.12 (mg Br per 1L).
The hydrogel produced was injected to a female patient L-ya, aged 26, to replace a silicone prosthesis which had been used for primary mammaplasty 3 years before and caused fibrosis of both mammals 7 months after the operation. Surgery was performed to remove silicone prosthesis with open capsulotomy and delayed injection of 180 g of hydrogel to each mammal. 3 months later another 100 g of the same hydrogel was injected to each mammal. The patient was being seen for 7 months' post-operative period with once-every-two-months examinations. Fibrosis recurrence was not detected. As a result of surgery mammals' shape and size fit patient's constitu- tion, their elasticity was typical for tissue of healthy mammal. A desirable cosmetic effect was obtained.
Results of the use of the claimed biocompatible hydrogel were published in the following papers: "Polyacrylamide gel in aesthetic surgery" (see Annals of Anaplastic, Reconstructive and Aesthetic Surgery, 1997, No.2, p.7-
9), A.I.Nerobeev et al "Experience with the use of polyacrylamide gel for contour plastics of soft tissues" (see the same as above, p.22-29), G.I.Lu- komsky et al "Formacryl for mammaplasty and treatment of capsular fibro- ses" (see the same as above, pp.30-34), M.A.Sulamanidze et al "Subcutaneo- us dissection and liquid-gel dermotension" (see the same as above, pp.35-38),
"Capsular Fibrosis and its Treatment after Mammaplasty with Silicone En- doprostheses" (see the same as above, pp.75-87).
Thus, examples given prove possibility of producing biocompatible hydrogel and of using it for plastics of soft tissues. Such a hydrogel can also be used as a filling agent for endoprostheses comprising a cover and a filling agent.

Claims

Clai s
1. Biologically compatible hydrogel for endoprosthetics containing cross- linked copolymer of acrylamide with a linking agent and water wherein said linking agent is a mixture of N,N'-methylene-bis-acrylamide and N,N'- ethylene-bis-acrylamide, with acrylamide to N,N' -methylene-bis-acrylamide and N,N'-ethylene-bis-acrylamide mass ratio being 95.0-99.5 : 0.4-4,5 : 0.1- 0,5 respectively.
2. The hydrogel of claim 1 wherein said cross-linked copolymer contains structural groups (HC-NH-CH), (-CO-NH-CR-O-R), (-CO-NH-NH-CO-), (H- COR-NH-CR-O-R), (-CONH-R-NH-CO), where R = CH3, CH2, NH2, C2H5.
3. The hydrogel of claim 1 wherein its pH is 4.5-7.5.
4. The hydrogel of claim 1 wherein said cross-linked copolymer comprises 2 to 15%) of total hydrogel weight.
5. The hydrogel of claim 1 wherein it contains twice-distilled apyroginic water as aqueous medium.
6. The biocompatible hydrogel of claim 1 wherein it is obtained by copolymerization of acrylamide with N, N'-methylene-bis-acrylamide and N,N'- ethylene-bis-acrylamide, their mass ratio is 95.0-99.5 : 0,4-4,5 : 0.1-0.5 in aqueous medium in the presence of peroxide polymerization initiator with reaction mass incubation at 20-90°C for 2-24 hours and then at 115-130°C for 1-1.5 hours, with semi-product washing in hot water at 90-100°C for 4-6 hours which follows reaction mass incubation at 20-90 °C.
7. The hydrogel of claim 6 wherein semi-product washing is carried out at semi-product to water mass ratio of 1 :8-10.
8. The hydrogel of claim 6 wherein hydrogen peroxide and/or ammonium persulfate are used as polymerization initiators; their content does not exceed 0.3% wt.
9. The biologically compatible hydrogel for endoprosthetics containing cross-linked copolymer of acrylamide with a linking agent and water wherein it contains as a linking agent mixture of acrylamide with N, N'-methylene- bis-acrylamide, N, N'-ethylene-bis-acrylamide and ethylene-bis-(oxyethylene nitril)-tetracetic oxide or ethylene-bis-(oxyethylene nitril)-tetracetic acid with their mass ratio of 95.0-99.5 : 0,4-4,5 : 0.08-0.4 : 0.02-0.1.
10. The hydrogel of claim 9 wherein said cross-linked copolymer contains structural groups (HC-NH-CH), (-CO-NH-CR-O-R), (-CO-NH-NH-CO-), (H- COR-NH-CR-O-R), (-CONH-R-NH-CO), where R = CH3, CH2, NH2, C2H5.
1 1. The hydrogel of claim 9 wherein its pH is 4.5-7.5.
12. The hydrogel of claim 9 wherein said cross-linked copolymer comprises 2 to 15%) of total hydrogel weight.
13. The hydrogel of claim 9 wherein it contains twice-distilled apyroginic water as aqueous medium.
14. The hydrogel of claim 9 wherein it is obtained by copolymerization of acrylamide, N, N'-methylene-bis-acrylamide, N, N'-ethylene-bis-acrylamide and ethylene-bis-(oxyethylene nitril)-tetracetic oxide or ethylene-bis-(ox- yethylene nitril)-tetracetic acid with their mass ratio of 95.0-99.5 : 0,4-4,5 : 0.08-0.4 : 0.02-0.1 in aqueous medium in the presence of peroxide polymeri- zation initiator with reaction mass incubation at 20-90 °C for 2-24 hours and then at 115-130°C for 1-1.5 hours, with semi-product washing in hot water at 90-100°C for 4-6 hours which follows reaction mass incubation at 20-90°C.
15. The hydrogel of claim 14 wherein semi-product washing is carried out at semi-product to water mass ratio of 1 :8-10.
16. The hydrogel of claim 14 wherein hydrogen peroxide and/or ammonium persulfate are used as polymerization initiators; their content does not exceed 0.3%> wt.
17. A method of producing biocompatible hydrogel by copolymerization of acrilamide with a linking agent in aqueous medium in the presence of peroxi- de polymerization initiator, with two-staged incubation of reaction mass, the first stage being held at temperature of 20-90 °C for 2-24 hours, wherein mixture of N, N'-methylene-bis-acrylamide and N, N'-ethylene-bis-acrylamide is used as the linking agent; the second stage of incubation is held at 1 15- 130°C within 1-1.5 hours; the first incubation stage is followed by semi-pro- duct washing in hot water at 90-100°C for 4-6 hours.
18. The method of claim 17 wherein acrylamide, N, N'-methylene-bis- acrylamide and N, N'-ethylene-bis-acrylamide are taken in mass ratio of
95.0-99.5 : 0,4-4,5 : 0.1 -0.5.
19. The method of claim 17 wherein semi-product washing is carried out at semi-product to water mass ratio of 1 :8-10.
20. The method of claim 17 wherein hydrogen peroxide and/or ammonium 5 persulfate are used as polymerization initiators; their content does not exceed
0.3%) wt.
21. The method of claim 17 wherein twice-distilled apyroginic water is used as aqueous medium.
22. The method of claim 17 wherein aqueous medium and mixture of o acrylamide, N, N'-methylene-bis-acrylamide and N, N'-ethylene-bis-acrylamide are taken in initial mass of water to monomers mixture of 85.0-98.0 : 2.0-15.0 wt parts.
23. A method of producing biocompatible hydrogel by copolymerization of acrilamide with a linking agent in aqueous medium in the presence of peroxi- 5 de polymerization initiator, with two-staged incubation of reaction mass, the first stage being held at temperature of 20-90°C for 2-24 hours, wherein mixture of N, N'-methylene-bis-acrylamide and N, N'-ethylene-bis-acrylamide and ethylene-bis-(oxyethylene nitril)-tetracetic oxide or ethylene-bis-(ox- yethylene nitril)-tetracetic acid is used as the linking agent; the second stage o of incubation is held at 1 15-130°C within 1-1.5 hours; the first incubation stage is followed by semi-product washing in hot water at 90-100°C for 4-6 hours.
24. The method of claim 23 wherein acrylamide, N, N'-methylene-bis- acrylamide, N, N'-ethylene-bis-acrylamide and ethylene-bis-(oxyethylene 5 nitril)-tetracetic oxide or ethylene-bis-(oxyethylene nitril)-tetracetic acid are taken with mass ratio of 95.0-99.5 : 0,4-4,5 : 0.08-0.4 : 0.02-0.1.
25. The method of claim 23 wherein semi-product washing is carried out at semi-product to water mass ratio of 1 :8-10.
26. The method of claim 23 wherein hydrogen peroxide and/or ammonium 0 persulfate are used as polymerization initiators; their content does not exceed
0.3% wt.
27. The method of claim 23 wherein twice-distilled apyroginic water is used as aqueous medium.
28. The method of claim 23 wherein water medium and mixture of acrylamide, N, N'-methylene-bis-acrylamide, N, N'-ethylene-bis-acrylamide and ethylene-bis-(oxyethylene nitril)-tetracetic oxide or ethylene-bis-(oxyethyle- ne nitril)-tetracetic acid are taken in initial water to monomers mixture ratio of 85.0-98.0 : 2.0-15.0 wt parts.
PCT/IT1999/000428 1999-12-29 1999-12-29 Biocompatible hydrogel and method of its production Ceased WO2001049336A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/IT1999/000428 WO2001049336A1 (en) 1999-12-29 1999-12-29 Biocompatible hydrogel and method of its production
AU20019/00A AU2001900A (en) 1999-12-29 1999-12-29 Biocompatible hydrogel and method of its production

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT1999/000428 WO2001049336A1 (en) 1999-12-29 1999-12-29 Biocompatible hydrogel and method of its production

Publications (1)

Publication Number Publication Date
WO2001049336A1 true WO2001049336A1 (en) 2001-07-12

Family

ID=11333137

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT1999/000428 Ceased WO2001049336A1 (en) 1999-12-29 1999-12-29 Biocompatible hydrogel and method of its production

Country Status (2)

Country Link
AU (1) AU2001900A (en)
WO (1) WO2001049336A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016453A1 (en) * 2000-08-25 2002-02-28 Contura S.A. Polyacrylamide hydrogel and its use as an endoprosthesis
WO2003087170A1 (en) * 2002-04-10 2003-10-23 Gradipore Limited Polyacrylamide hydrogels
US7186419B2 (en) 2000-08-25 2007-03-06 Contura Sa Polyacrylamide hydrogel for arthritis
US7238761B2 (en) 2002-04-10 2007-07-03 Obschestvos Organichennoy Otvetstvennostyu “Vitagel” Multifunctional biocompatible hydrophilic gel and the method of gel manufacture
US7294348B2 (en) * 2001-09-28 2007-11-13 Biopharma Development, Ltd. Polyfunctional biocompatible hydrogel and method for the production thereof
US7678146B2 (en) 2000-08-25 2010-03-16 Contura A/S Polyacrylamide hydrogel and its use as an endoprosthesis
US8496943B2 (en) * 2003-03-31 2013-07-30 Durect Corporation Non-aqueous single phase vehicles and formulations utilizing such vehicles
US11083796B2 (en) 2005-07-26 2021-08-10 Durect Corporation Peroxide removal from drug delivery vehicle
US11400019B2 (en) 2020-01-13 2022-08-02 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
US12433877B2 (en) 2021-01-12 2025-10-07 Durect Corporation Sustained release drug delivery systems and related methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4074039A (en) * 1970-03-26 1978-02-14 Ceskoslovenska Akademie Ved Hydrophilic N,N-diethyl acrylamide copolymers
EP0742022A1 (en) * 1994-08-10 1996-11-13 Maloe Vnedrencheskoe Predpriyatie "Interfall" Biologically compatible hydrogel
RU2122438C1 (en) * 1998-02-25 1998-11-27 ООО "Космогель" Method of preparing polymer hydrogel
RU2127129C1 (en) * 1996-05-28 1999-03-10 Владислав Викторович Лопатин Method of preparing gel-like material for plastics of soft tissues

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4074039A (en) * 1970-03-26 1978-02-14 Ceskoslovenska Akademie Ved Hydrophilic N,N-diethyl acrylamide copolymers
EP0742022A1 (en) * 1994-08-10 1996-11-13 Maloe Vnedrencheskoe Predpriyatie "Interfall" Biologically compatible hydrogel
RU2127129C1 (en) * 1996-05-28 1999-03-10 Владислав Викторович Лопатин Method of preparing gel-like material for plastics of soft tissues
RU2122438C1 (en) * 1998-02-25 1998-11-27 ООО "Космогель" Method of preparing polymer hydrogel

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 200015, Derwent World Patents Index; Class A14, AN 2000-170073, XP002146497 *
DATABASE WPI Section Ch Week 200025, Derwent World Patents Index; Class A14, AN 2000-291292, XP002146496 *
OPPERMANN W., SCHRÖDER U.P., LINDEMANN B.: "Influence of the Cross-Linker Reactivity on the Formation of Inhomogeneities in Hydrogels", MACROMOLECULES, vol. 30, 1997, pages 4073 - 4077, XP002146495 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935361B2 (en) 2000-08-25 2011-05-03 Contura A/S Polyacrylamide hydrogel as a soft tissue filler endoprosthesis
US8216561B2 (en) 2000-08-25 2012-07-10 Contura A/S Polyacrylamide hydrogel for the treatment of incontinence and vesicouretal reflex
EP1564230A2 (en) 2000-08-25 2005-08-17 Contura S.A. Polyacrylamide hydrogel and its use as an endoprosthesis
US7186419B2 (en) 2000-08-25 2007-03-06 Contura Sa Polyacrylamide hydrogel for arthritis
WO2002016453A1 (en) * 2000-08-25 2002-02-28 Contura S.A. Polyacrylamide hydrogel and its use as an endoprosthesis
EP1564230A3 (en) * 2000-08-25 2009-12-09 Contura A/S Polyacrylamide hydrogel and its use as an endoprosthesis
US7678146B2 (en) 2000-08-25 2010-03-16 Contura A/S Polyacrylamide hydrogel and its use as an endoprosthesis
US7780958B2 (en) 2000-08-25 2010-08-24 Contura Sa Polyacrylamide hydrogel for the treatment of incontinence and vesicouretal reflux
US7790194B2 (en) 2000-08-25 2010-09-07 Contura A/S Polyacrylamide hydrogel as a soft tissue filler endoprosthesis
US7294348B2 (en) * 2001-09-28 2007-11-13 Biopharma Development, Ltd. Polyfunctional biocompatible hydrogel and method for the production thereof
US7238761B2 (en) 2002-04-10 2007-07-03 Obschestvos Organichennoy Otvetstvennostyu “Vitagel” Multifunctional biocompatible hydrophilic gel and the method of gel manufacture
WO2003087170A1 (en) * 2002-04-10 2003-10-23 Gradipore Limited Polyacrylamide hydrogels
US8496943B2 (en) * 2003-03-31 2013-07-30 Durect Corporation Non-aqueous single phase vehicles and formulations utilizing such vehicles
US11083796B2 (en) 2005-07-26 2021-08-10 Durect Corporation Peroxide removal from drug delivery vehicle
US11400019B2 (en) 2020-01-13 2022-08-02 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
US11771624B2 (en) 2020-01-13 2023-10-03 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
US12433877B2 (en) 2021-01-12 2025-10-07 Durect Corporation Sustained release drug delivery systems and related methods

Also Published As

Publication number Publication date
AU2001900A (en) 2001-07-16

Similar Documents

Publication Publication Date Title
RU2205034C1 (en) Polyfunctional biocompatible hydrogel and method for its preparing
KR101382083B1 (en) Interpenetrating Networks, and Related Methods and Compositions
JP7509437B2 (en) Zwitterionic double network hydrogels
RU2230752C2 (en) Cross-linked hyaluronic acids and their application in medicine
JPH10503950A (en) Biocompatible hydrogel
KR20220014164A (en) Hydrogel composite comprising gelatin and synthetic polymer, and process for preparing the same
WO2001049336A1 (en) Biocompatible hydrogel and method of its production
ZA200208717B (en) Polyacrylamide hydrogel and its use as an endoprosthesis.
Rezaei et al. Grafting of collagen onto interpenetrating polymer networks of poly (2-hydroxyethyl methacrylate) and poly (dimethyl siloxane) polymer films for biomedical applications.
NZ536201A (en) Polyfunctional biocompatible hydrogel and method for the production thereof
RU2127129C1 (en) Method of preparing gel-like material for plastics of soft tissues
Concordio-Reis et al. Iron (III) cross-linked hydrogels based on Alteromonas macleodii Mo 169 exopolysaccharide
Turaev Dependence of the biodegradability of carboxymethylcellulose on its supermolecular structure and molecular parameters
TWI908439B (en) Bilateral heterogeneous polymer-based artificial intraocular lens, preparation process thereof and use for antifouling, anti-cell migration, anti-inflammation and anti-posterior capsule opacification
KR102922003B1 (en) Polysaccharide-based multi-functional hydrogel
EP4454670A1 (en) Polymer-ceramic biocomposites with pro-regenerative properties for filing bone defects and regenerating bone tissue and method of obtaining them
RU2150956C1 (en) Method of biocompatible material producing
EP3533806A1 (en) Gel composition and method for producing same
KR20250009763A (en) Polysaccharide-based multi-functional hydrogel
CN113087861A (en) Modified hydrogel with mild photothermal effect and preparation method and application thereof
CA2667708A1 (en) Hydrogel systems
Alsalami Asian Journal of Green Chemistry
Rauh et al. 20 Complex Polysaccharides
Duan DENDRIMER CROSSLINKED COLLAGEN SCAFFOLDS FOR
Duan Dendrimer Crosslinked Collagen Scaffolds for Corneal Tissue Engineering

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase